BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang, Z., Yuan, X., Du, R., Cheung, S.H., Zhang, G., Wei, J., Zhao, Y., Feng, Y., Peng, H., Zhang, Y., Du, Y., Hu, X., Gong, W., Liu, Y., Gao, Y., Liu, Y., Hao, R., Li, S., Wang, S., Ji, J., Zhang, L., Li, S., Sutton, D., Wei, M., Zhou, C., Wang, L., Luo, L.(2015) Mol Cancer Ther 14: 2187-2197
- PubMed: 26208524 
- DOI: 10.1158/1535-7163.MCT-15-0262
- Primary Citation of Related Structures:  
4R5Y - PubMed Abstract: 
Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive ...